Eli Lilly & Co. (NYSE: LLY) announced positive topline results from its SURMOUNT-OSA Ph3 study on Wednesday, which evaluated tirzepatide ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE